Table 3.
Group‐L (n = 1,177) | Group‐H (n = 1,173) | |
---|---|---|
<23.33 ng/mL | ≥23.33 ng/mL | |
T2DM | ||
Unadjusted | 1 | 3.497 (1.955–6.255)** |
Model 1 | 1 | 2.562 (1.416–4.635)* |
Model 2 | 1 | 2.759 (1.495–5.089)* |
Model 3 | 1 | 2.107 (1.123–3.955)* |
Model 4 | 1 | 1.988 (1.052–3.758)* |
IFG | ||
Unadjusted | 1 | 2.657 (1.954–3.613)** |
Model 1 | 1 | 2.000 (1.457–2.746)** |
Model 2 | 1 | 2.106 (1.528–2.902)** |
Model 3 | 1 | 1.752 (1.258–2.439)* |
Model 4 | 1 | 1.626 (1.162–2.274)* |
Insulin resistance | ||
Unadjusted | 1 | 1.754 (1.426–2.159)** |
Model 1 | 1 | 1.702 (1.372–2.112)** |
Model 2 | 1 | 1.673 (1.346–2.078)** |
Model 3 | 1 | 1.359 (1.080–1.710)* |
Model 4 | 1 | 1.034 (0.807–1.326) |
Data were analyzed by odds ratios and 95% confidence intervals. *P < 0.05, **P < 0.001 (logistic regression was used to calculate the odds ratios for type 2 diabetes mellitis [T2DM], impaired fasting glucose [IFG] and insulin resistance). Model 1 was adjusted for age. Model 2 was further adjusted for cigarette smoking and education level. Model 3 was further adjusted for total cholesterol, triglyceride, high‐density lipoprotein and low‐density lipoprotein. Model 4 was further adjusted for body mass index. Group‐H, osteocalcin level ≥23.33 ng/mL; group‐L, osteocalcin level <23.33 ng/mL.